Eversept Partners LP Buys 40,807 Shares of Icon Plc $ICLR

Eversept Partners LP raised its stake in Icon Plc (NASDAQ:ICLR) by 74.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 95,832 shares of the medical research company’s stock after acquiring an additional 40,807 shares during the period. Icon makes up 0.9% of Eversept Partners LP’s portfolio, making the stock its 27th largest holding. Eversept Partners LP owned approximately 0.12% of Icon worth $17,463,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Sanctuary Advisors LLC increased its holdings in Icon by 1.1% in the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after acquiring an additional 56 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares during the last quarter. New Wave Wealth Advisors LLC increased its holdings in Icon by 5.1% in the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 72 shares during the last quarter. Signaturefd LLC increased its holdings in Icon by 12.6% in the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after acquiring an additional 72 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in Icon by 0.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after acquiring an additional 93 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ICLR has been the topic of a number of research reports. Bank of America reiterated an “outperform” rating on shares of Icon in a report on Monday, June 1st. Piper Sandler downgraded shares of Icon to a “neutral” rating in a report on Thursday, May 28th. Zacks Research downgraded shares of Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Royal Bank Of Canada boosted their target price on shares of Icon from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Friday, May 29th. Finally, Barclays boosted their target price on shares of Icon from $120.00 to $150.00 and gave the stock an “equal weight” rating in a report on Friday, May 29th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $156.44.

Icon Stock Performance

Icon stock opened at $143.27 on Thursday. The company’s 50-day moving average price is $123.69 and its 200-day moving average price is $139.54. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. The company has a market cap of $10.97 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 11.34 and a beta of 1.26.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, June 17th. The medical research company reported $2.52 earnings per share for the quarter, topping analysts’ consensus estimates of $2.47 by $0.05. Icon had a net margin of 5.98% and a return on equity of 9.50%. The firm had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $1.99 billion. During the same period in the previous year, the firm posted $3.43 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. On average, equities research analysts forecast that Icon Plc will post 9.74 EPS for the current fiscal year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.